In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon

Am J Infect Control. 2005 Apr;33(3):134-6. doi: 10.1016/j.ajic.2004.10.006.

Abstract

Looking for therapeutic options, we assessed the minimum inhibitory concentrations (MICs) of 7 antimicrobial agents against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (n = 58) and Escherichia coli (n = 84) isolates. High rates of susceptibility were shown for both E coli and K pneumoniae against ertapenem (100% for both), piperacillin/tazobactam (83% and 91%, respectively) and amikacin (96% and 82%, respectively). In addition, most K pneumoniae isolates were susceptible to quinolones (72%-75%) and cefepime (88%). However, clinical correlation is warranted.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology*
  • Child
  • Child, Preschool
  • Drug Resistance, Multiple, Bacterial
  • Escherichia coli / drug effects*
  • Escherichia coli / enzymology
  • Escherichia coli Infections / microbiology
  • Female
  • Hospitals, University
  • Humans
  • Infant
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / enzymology
  • Lebanon
  • Male
  • Middle Aged
  • beta-Lactamases / biosynthesis

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases